Janssen

Janssen Therapeutics, USAID collaborate on antimicrobial resistance

Monday, December 15, 2014 12:32 PM

Janssen Therapeutics, a Johnson & Johnson affiliate, has signed a memorandum of understanding (MOU) with the U.S. Agency for International Development (USAID) to step up the fight against the health threat of antibiotic-resistant bacteria.

More... »


Pharmacyclics launches informCLL registry for CLL patients

Friday, December 5, 2014 12:37 PM

Pharmacyclics, a Sunnyvale, Calif.-based biopharmaceutical company, has launched informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how Imbruvica (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, and the registry is a joint effort between the companies. Registry enrollment will begin in the first half of 2015.

More... »


Geron, Janssen collaborate to develop and commercialize imetelstat

Monday, November 17, 2014 02:36 PM

Geron, a Menlo Park, Calif.-based clinical stage biopharmaceutical company, has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies and other human therapeutics uses.

More... »

Recipharm acquires Lusomedicamenta

Friday, November 14, 2014 02:21 PM

Recipharm, a Swedish pharmaceutical contract development and manufacturing organization (CDMO), has acquired Lisbon, Portugal-based CDMO Lusomedicamenta Sociedade Técnica Farmacêutica.

More... »

FDA approves sNDAs for Invega Sustenna for schizoaffective disorder

Thursday, November 13, 2014 02:22 PM

The FDA has approved Janssen Pharmaceutical's supplemental New Drug Applications (sNDAs) for the once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to treat schizoaffective disorder as either monotherapy or adjunctive therapy. The symptoms of schizoaffective disorder are complex and, without treatment, disabling. The FDA approved these sNDAs under Priority Review, which is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions.

More... »

AstraZeneca, Pharmacyclics, Janssen partner

Wednesday, November 5, 2014 12:37 PM

AstraZenecaPharmacyclics and Janssen R&D have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech. The study will assess the combination as a treatment for patients with hematologic cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.

More... »

Johnson & Johnson Innovation, University of Toronto collaborate

Wednesday, October 29, 2014 01:18 PM

Janssen has signed an agreement, facilitated by the Johnson & Johnson Innovation center in California, with the University of Toronto's Center for Collaborative Drug Research (CCDR) to form an open-source collaboration focused on novel therapeutic approaches to the treatment and management of mood disorders and Alzheimer's disease.

More... »

J&J Innovation adds J-Labs incubator at Texas Medical Center

Friday, October 24, 2014 01:07 PM

Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center's new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.

More... »

Johnson & Johnson to speed Ebola vaccine development, expand production

Thursday, October 23, 2014 01:03 PM

Johnson & Johnson has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen.

More... »

Aduro, Johnson & Johnson Innovation and Janssen expand collaboration

Friday, October 17, 2014 12:44 PM

Aduro BioTech, a Berkeley, Calif.-based, private, clinical-stage biotechnology company focused on immunotherapy for cancer, has entered into its second agreement with Janssen Biotech, part of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs